南宫NG28

Be the most trusted biotech company

2025-09-08

Henlius Showcased 9 Study Findings on Serplulimab at 2025 WCLC with 3 Oral Presentations
2025-09-07

The Updated Clinical Results for PD-L1 ADC HLX43 at the 2025 WCLC, Demonstrate Outstanding Efficacy in NSCLC
2025-09-05

FUTUONING Sets Sail Commercially with First Prescriptions Across China
2025-09-02

US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2025-08-28

Henlius to Participate in Citi’s 2025 Biopharma Back to School Summit
2025-08-28

Henlius Featured at the 2025 Evercore China Biotech Summit
2025-08-25

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
2025-08-22

First Subject Dosed in the US for a Phase 2 International Clinical Trial of Henlius’ PD-L1 ADC HLX43 for NSCLC
2025-08-21

Henlius’ Serplulimab Prescribed for the First Time in Both Europe and India, Marking a Milestone Toward Global Accessibility

1
...
3
4
5
6
7
8
...
14